Drug Trial Radar · NCT01374581
Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria
Last checked: Nov 19, 2026Latest source record: Oct 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,117
Actual
Start
May 2012
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Universiteit AntwerpenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European and Developing Countries Clinical Trials Partnership (EDCTP); Fund for Scientific Research, Flanders, Belgium; Institute of Tropical Medicine, Belgium; University of Kinshasa; Centre Muraz; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Makerere University
- First posted
- Jun 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 months, up to 59 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug) and artesunate-amodiaquine (ASAQ) in RDCongo, on malaria incidence and its potential selection of resistant strains. Patients will be followed-up for efficacy and safety during 42 days after treatment with the first line therapy recommended by the national authorities(arthemeter-lumefantrine in Uganda and artesunate-amodiaquine in RDCongo) and retreated the patients either with the same ACT or an other ACT or oral Quinine + clyndamicin. The investigators hypothesize that (re)treatment with the first line ACT treatment beyond 14 days is as efficacious as any other rescue treatment, without the risk of selecting drug resistant strains.
Conditions
- Malaria
Interventions
Artemether/LumefantrineDrug
Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk). Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose
Artesunate/AmodiaquineDrug
Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days 1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days
Quinine + ClindamycinDrug
this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow; Quinine: 9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose Clindamycin syrup: 10 mg/kg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Late Parasitological FailureTime frame: Day4-Day28
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Centre de Santé Lisungi
Kinshasa, Mont-Ngafula, Republic of the Congo
Kazo Health centre IV
Kiruhura, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.